Logo image of TVGN

TEVOGEN BIO HOLDINGS INC (TVGN) Stock Fundamental Analysis

USA - NASDAQ:TVGN - US88165K1016 - Common Stock

0.4555 USD
-0.01 (-2.19%)
Last: 11/13/2025, 10:54:26 AM
Fundamental Rating

1

TVGN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. TVGN may be in some trouble as it scores bad on both profitability and health. TVGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

TVGN had positive earnings in the past year.
TVGN had a negative operating cash flow in the past year.
TVGN Yearly Net Income VS EBIT VS OCF VS FCFTVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2021 2022 2023 0 2M -2M 4M

1.2 Ratios

With an excellent Return On Assets value of 337.72%, TVGN belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 14.78%, TVGN belongs to the top of the industry, outperforming 95.48% of the companies in the same industry.
Industry RankSector Rank
ROA 337.72%
ROE N/A
ROIC 14.78%
ROA(3y)0.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVGN Yearly ROA, ROE, ROICTVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2021 2022 2023 0 5 -5 -10

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVGN Yearly Profit, Operating, Gross MarginsTVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2021 2022 2023

1

2. Health

2.1 Basic Checks

The number of shares outstanding for TVGN has been increased compared to 1 year ago.
The debt/assets ratio for TVGN is higher compared to a year ago.
TVGN Yearly Shares OutstandingTVGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M 150M
TVGN Yearly Total Debt VS Total AssetsTVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.05 indicates that TVGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.05, TVGN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 2.05
ROIC/WACCN/A
WACCN/A
TVGN Yearly LT Debt VS Equity VS FCFTVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

TVGN has a Current Ratio of 0.12. This is a bad value and indicates that TVGN is not financially healthy enough and could expect problems in meeting its short term obligations.
TVGN has a Current ratio of 0.12. This is amonst the worse of the industry: TVGN underperforms 96.42% of its industry peers.
A Quick Ratio of 0.12 indicates that TVGN may have some problems paying its short term obligations.
TVGN's Quick ratio of 0.12 is on the low side compared to the rest of the industry. TVGN is outperformed by 96.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
TVGN Yearly Current Assets VS Current LiabilitesTVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M

1

3. Growth

3.1 Past

TVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 375.00%, which is quite impressive.
EPS 1Y (TTM)375%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%640%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 1.20, the valuation of TVGN can be described as very cheap.
99.62% of the companies in the same industry are more expensive than TVGN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, TVGN is valued rather cheaply.
Industry RankSector Rank
PE 1.2
Fwd PE N/A
TVGN Price Earnings VS Forward Price EarningsTVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVGN Per share dataTVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for TVGN!.
Industry RankSector Rank
Dividend Yield N/A

TEVOGEN BIO HOLDINGS INC

NASDAQ:TVGN (11/13/2025, 10:54:26 AM)

0.4555

-0.01 (-2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-25 2026-03-25
Inst Owners2.57%
Inst Owner Change-0.66%
Ins Owners79.36%
Ins Owner Change5.43%
Market Cap89.60M
Revenue(TTM)N/A
Net Income(TTM)57.54M
Analysts82.86
Price Target10.2 (2139.3%)
Short Float %5.25%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.2
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.38
EY83.42%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 337.72%
ROE N/A
ROCE 20.88%
ROIC 14.78%
ROICexc 14.78%
ROICexgc 14.78%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)0.28%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z 2.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)375%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%640%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y408.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-525.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-525.64%
OCF growth 3YN/A
OCF growth 5YN/A

TEVOGEN BIO HOLDINGS INC / TVGN FAQ

What is the fundamental rating for TVGN stock?

ChartMill assigns a fundamental rating of 1 / 10 to TVGN.


What is the valuation status for TVGN stock?

ChartMill assigns a valuation rating of 2 / 10 to TEVOGEN BIO HOLDINGS INC (TVGN). This can be considered as Overvalued.


How profitable is TEVOGEN BIO HOLDINGS INC (TVGN) stock?

TEVOGEN BIO HOLDINGS INC (TVGN) has a profitability rating of 2 / 10.


What is the valuation of TEVOGEN BIO HOLDINGS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVOGEN BIO HOLDINGS INC (TVGN) is 1.2 and the Price/Book (PB) ratio is -128.74.


Can you provide the financial health for TVGN stock?

The financial health rating of TEVOGEN BIO HOLDINGS INC (TVGN) is 1 / 10.